Your browser does not support the NLM PubReader view.

Go to this page to see a list of supporting browsers.

Diagnostic value of BRAFV600E mutation analysis in fine needle aspiration for evaluation of thyroid nodules

Article information

Kosin Med J. 2018;33(1):1-11
Publication date (electronic) : 2018 January 21
doi : https://doi.org/10.7180/kmj.2018.33.1.1
Hae Won Lee1, So Young Ock1, Bu Kyoung Kim1, Su Kyoung Kwon1, Young Sik Choi,1, Jeong Hoon Kim2, Sang Bong Jung3
1Departments of Internal Medicine, College of Medicine, Kosin University, Busan, Korea
2Department of General Surgery, College of Medicine, Kosin University, Busan, Korea
3Department of Clinical Laboratory Science, Dong-Eui Institute of Technology, Busan, Korea
Corresponding Author: Young Sik Choi, Department of Internal Medicine, College of Medicine, Kosin University, 262, Gamcheon-ro, Seo-gu, Busan 49267, Korea Tel: +82-51-990-6102 Fax: +82-51-248-5686 E-mail: yschoi@kosinmed.or.kr
Received 2016 January 08; 2016 March 15; Accepted 2016 April 20.

Abstract

Objectives

Ultrasound-guided fine-needle aspiration (FNA) is routinely used in the evaluation of thyroid nodules. However, it has several pitfalls, as has been noted in nondiagnostic and indeterminate cases. This study aims to investigate the value of BRAFV600E mutation co-testing in FNA cytology.

Method

A total of 310 patients underwent BRAFV600E mutation co-testing in FNA cytology on thyroid nodules between June 2013 and June 2014. Of the 310 patients, 69 patients who had undergone a surgery for thyroid nodules were included in this study. The presence of the BRAFV600E mutation was determined by allele-specific polymerase chain reaction amplification of exon 15 of the BRAF gene.

Results

Of 69 cases, 33 (47.8%) were BRAFV600E mutation positive. The BRAFV600E mutation was not significantly associated with high-risk features such as tumor size, lymph node metastasis, and pathological stage. The respective diagnostic performance of FNA (P = 0.02), BRAFV600E mutation (P = 0.03), and ultrasonographic (P = 0.00) findings was statistically significant. The sensitivity, specificity and positive predictive value of FNA was 64.9%, 83.3%, and 94.8%. The sensitivity, specificity and positive predictive value of BRAFV600E mutation was 56.1%, 91.7%, and 96.9% and the US features was 91.2%, 91.7%, and 98.1% respectively. However, sensitivity of FNA with BRAFV600E mutation (77.2%) was lower than FNA with US (92.9%) and combination all together (92.9%).

Conclusion

In this study, we found that US features were the most useful in preoperative differential diagnosis of thyroid nodules. BRAFV600E mutation co-testing in FNA cytology was also useful for diagnosis of thyroid tumors.

Keywords: BRAFV600E mutation; Fine-needle aspiration; Thyroid nodules; Ultrasound features

Fine-needle aspiration, BARFV600E, and final pathologic diagnosis with operation in thyroid nodules

Correlation between BRAFV600E mutation and various clinicopathological parameters in papillary thyroid carcinomas

Sensitivity, specificity, positive predictive value and negative predictive value according to diagnostic modalities

References

1. Vander JB, Gaston EA, Dawber TR. The significance of nontoxic thyroid nodules: Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 1968;69:537–40.
2. Hegedüs L. Clinical practice: the thyroid nodule. N Engl J Med 2004;351:1764–71.
3. Tan GH, Gharib H. Thyroid incidentalomas: Management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997;126:226–31.
4. Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med 1994;154:1838–40.
5. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993;328:553–9.
6. Nga ME, Kumarasinghe MP, Tie B, Sterrett GF, Wood B, Walsh J, et al. Experience with standardized thyroid fine-needle aspiration reporting categories: follow-up data from 529 cases with “indeterminate” or “atypical” reports. Cancer Cytopathol 2010;118:423–33.
7. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167–214.
8. Moon WJ, Jung SL, Lee JH, Na DG, Baek JH, Lee YH, et al. Benign and malignant thyroid nodules: US differentiation-multicenter retrospective study. Radiology 2008;247:762–70.
9. Kim EK, Park CS, Chung WY, Oh KK, Kim DI, Lee JT, et al. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol 2002;178:687–91.
10. Yi KH, Park YJ, Koong SS, Kim JH, Na DG, Ryu JS, et al. Revised Korean Thyroid Association management guidelines for patients with thyroid nodules and thyroid cancer. J Korean Soc Radiol 2011;64:389–416.
11. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 2002;25:511–8.
12. Davies H, Bignell GR, Cox C, Stehens P, Edkins S, Clegg S. Mutations of the BRAF gene in human cancer. Nature 2002;417:949–54.
13. Ahn HY, Park YJ. Incidence and clinical characteristics of thyroid cancer in Korea. Korean J Med 2009;77:537–42.
14. Kwak JY, Kim EK, Kim HJ, Kim MJ, Son EJ, Moon HJ. How to combine ultrasound and cytological information in decision making about thyroid nodules. Eur Radiol 2009;19:1923–31.
15. Cibas ES, Ali SZ. NCI Thyroid FNA State of the Science Conference. The Bethesda System for reporting thyroid cytopathology. Am J Clin Pathol 2009;132:658–65.
16. Lipton RF, Abel MS. Aspiration Biopsy and the Thyroid in Evaluation of Thyroid Dysfunction. Am J Med Sci 1944;208:736–41.
17. Gharib H, Goellner JR. Fine needle aspiration biopsy of the thyroid: An appraisal. Ann Intern Med 1993;118:282–9.
18. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644–50.
19. Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab 2011;96:658–64.
20. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393–7.
21. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399–404.
22. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004;89:2414–20.
23. DiLorenzo MM, Miller JL, Tuluc M, Wang ZX, Savarese VW, Pribitkin EA. False-positive FNA due to highly sensitive BRAF assay. Endocr Pract 2014;20:e8–10.
24. Moon WJ, Choi N, Choi JW, Kim SK, Hwang TS. BRAF mutation analysis and sonography as adjuncts to fine-needle aspiration cytology of papillary thyroid carcinoma: their relationships and roles. AJR Am J Roentgenol 2012;198:668–74.
25. Seo JY, Kim EK, Baek JH, Shin JH, Han KH, Kwak JY. Can ultrasound be as a surrogate marker for diagnosing a papillary thyroid cancer? Comparison with BRAF mutation analysis. Yonsei Med J 2014;55:871–8.
26. Koike E, Noguchi S, Yamachita H, Murakami T, Ohshima A, Kawamoto H, et al. Ultrasonographic characteristics of thyroid nodules; prediction of malignancy. Arch Surg 2001;136:334–7.

Article information Continued

Copyright © 2018 Kosin University School of Medicine Proceedings

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Table 1.

Fine-needle aspiration, BARFV600E, and final pathologic diagnosis with operation in thyroid nodules

FNA result BRAFV600E mutation Numbers Pathology (n = 69)
Nondiagnostic (n = 3) Negative 3 PTC (n = 3)
Positive 0 None
Benign (n = 17) Negative 14 NH (n = 3), FA (n = 3), FC (n = 2), FVPTC (n = 1), PTC (n = 5)
Positive 3 FA (n = 1), PTC (n = 2)
AUS (n = 7) Negative 3 HT (n = 1), PTC (n = 2)
Positive 4 PTC (n = 4)
Suspicious for FN (n = 3) Negative 2 NH (n = 1), FA (n = 1)
Positive 1 FC (n = 1)
Suspicious for PTC (n = 7) Negative 4 NH (n = 1), HT (n = 1), PTC (n = 2)
Positive 3 PTC (n = 3)
PTC (n = 32) Negative 10 PTC (n = 10)
Positive 22 PTC (n = 22)

FAN, fine needle aspiration; AUS, atypia undetermined significance; FN, follicular neoplasm; PTC, papillary thyroid carcinoma; NH, nodular hyperplasia; FA, follicular adenoma; HT, Hashimoto’s thyroiditis; FC, follicular carcinoma; FVPTC, follicular variant papillary thyroid carcinoma

Table 2.

Correlation between BRAFV600E mutation and various clinicopathological parameters in papillary thyroid carcinomas

Mutation of BRAFV600E, n (%)
 X2 P-value
Wild (n = 23) Mutant (n = 31)
Age
< 45 years 9 (39.1) 12 (38.7) 0.001 0.59
≥ 45 years 14 (60.9) 19 (61.3)
Gender
Male 5 (21.7) 5 (16.1) 0.275 0.42
Female 18 (78.3) 26 (83.9)
Tumor size
≤ 10 ㎜ 21 (91.3) 24 (77.4) 1.833 0.16
> 10 ㎜ 2 (8.7) 7 (22.6)
Calcification
No 15 (65.2) 12 (38.7) 3.711 0.04
Yes 8 (34.8) 19 (61.3)
ETE
No 14 (60.9) 15 (48.4) 0.827 0.26
Yes 9 (39.1) 16 (51.6)
Lymphocytic thyroiditis
No 17 (73.9) 24 (77.4) 0.089 0.50
Yes 6 (26.1) 7 (22.6)
Nodal metastasis
Negative (N0) 19 (82.6) 19 (61.3) 2.878 0.08
Positive (N1a + N1b) 4 (17.4) 12 (38.7)
pTMN staging
I + II 20 (87.0) 25 (80.6) 0.379 0.40
III + IV 3 (13.0) 6 (19.4)

ETE; extrathyroidal extension. According to the TNM staging system: N1a indicates lymph node metastasis to level VI (pretracheal, tracheal and prelaryngeal nodes); N1b indicates metastasis to unilateral, bilateral, contralateral cervical or superior mediastinal nodes. Calculated by the χ2-test and Fisher’s exact test

Table 3.

Sensitivity, specificity, positive predictive value and negative predictive value according to diagnostic modalities

Sensitivity % Specificity % PPV % NPV % P-value
Cytology 64.9 (37/57) 83.3 (10/12) 94.8 (37/39) 66.7 (20/30) 0.02
BRAFV600E 56.1 (32/57) 91.7 (11/12) 96.9 (32/33) 30.1 (11/36) 0.03
US assessment 91.2 (52/57) 91.7 (11/12) 98.1 (52/53) 68.8 (11/16) 0.00
Cytology with BRAFV600E 77.2 (44/57) 75.0 (9/12) 93.6 (44/47) 40.9 (9/22) 0.00
Cytology with US 92.9 (53/57) 83.3 (10/12) 96.3 (53/55) 71.4 (10/14) 0.00
All combination 92.9 (53/57) 75.0 (9/12) 94.6 (53/56) 69.2 (9/13) 0.00

PPV; positive predictable value, NPV; negative predictable value